Research programme: cancer therapeutics - GENova

Drug Profile

Research programme: cancer therapeutics - GENova

Alternative Names: Prostaganin; Tetanolic acid

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GENova Biotherapeutics
  • Class Lipids; Oleic acids; Peptides; Stem cell therapies
  • Mechanism of Action Cell membrane structure modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Breast cancer; Prostate cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer in USA (Parenteral)
  • 14 Sep 2009 Compounds in research programme are available for licensing in worldwide as of 14 Sep 2009. http://www.genovabio.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top